Evidence map›Paper›PMID 40387572›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Activation of HTR2B Suppresses Osteosarcoma Progression through the STAT1-NLRP3 Inflammasome Pathway and Promotes OASL1+ Macrophage Production to Enhance Antitumor Immunity.

Zhen Huang, Jiazhuang Zhu, Jianping Hu, Xingkai Wang, Xiaolong Ma, Enjie Xu, Kunpeng Zhu, Chunlin Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Desloratadine as the selective 5HTJournal of neuroinflammation · 2025
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhen HuangDepartment of Orthopaedic, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Jiazhuang ZhuDepartment of Orthopaedic, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Jianping HuDepartment of Orthopaedic, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Xingkai WangDepartment of Orthopaedic, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Xiaolong MaDepartment of Orthopaedic, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Enjie XuDepartment of Orthopaedic, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Kunpeng ZhuDepartment of Orthopaedic, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Chunlin ZhangDepartment of Orthopaedic, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.ORCID https://orcid.org/0000-0003-3957-8603

Funding

Fundamental Research Funds for the Central Universities 22120240277National Natural Science Foundation of China 82072963National Natural Science Foundation of China 82103513National Natural Science Foundation of China 82303898Program for Research-oriented Physician of Shanghai Tenth People's Hospital 2023YJXYSC001Youth Projects for Clinical Research of Shanghai Municipal Health Commission 20224Y0136
6 · The paper itself

Abstract

Osteosarcoma is a primary malignant bone tumor originating from mesenchymal tissue, and associated with poor prognosis. The 5-hydroxytryptamine receptor 2B (HTR2B), a receptor for serotonin, is known to play a role in the progression of multiple tumors. This study aims to explore the potential roles of HTR2B in osteosarcoma progression. HTR2B expression is analyzed using the TARGET, GEO databases, and osteosarcoma tissue samples in the hospital. Lentivirus and agonist BW-723C86 are employed to assess HTR2B overexpression effects in osteosarcoma cell lines. Transcriptome sequencing analysis and single-cell sequencing are performed to identify potential downstream molecules and signaling pathways, and the changes in tumor immune microenvironment. The investigation demonstrates that HTR2B is downregulated in osteosarcoma tissues, and correlates with poorer survival outcomes. Upregulating HTR2B through lentiviral-mediated gene delivery or the agonist BW-723C86, resulted in a marked suppression of osteosarcoma cell progression via the STAT1-NLRP3 inflammasome pathway. Single-cell sequencing of CD45+ cells reveals that HTR2B activation enhances the production of OASL1+ macrophages, contributing to the observed enhancement of antitumor immunity. These findings propose HTR2B as a novel therapeutic target for treating osteosarcoma, offering a dual mechanism of action that directly impedes tumor cell proliferation and augments the host immune response.

Indexed as

Bone NeoplasmsInflammasomesMacrophagesNLR Family, Pyrin Domain-Containing 3 ProteinOsteosarcomaReceptor, Serotonin, 5-HT2BSTAT1 Transcription FactorCell Line, TumorDisease ProgressionHumansSignal TransductionTumor MicroenvironmentInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanReceptor, Serotonin, 5-HT2BSTAT1 protein, humanSTAT1 Transcription FactoractivationHTR2BOASL1+ macrophageosteosarcomaSTAT1‐NLRP3 inflammasome

Identifiers

PMID40387572
PMCPMC12362726

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.